Wuhan Humanwell Fukang Pharmaceutical Co., Ltd.
Wuhan Humanwell Fukang Pharmaceutical Co., Ltd.
No. 666, Donghugaoxinqugaoxin Avenue Renfuyiyaodong, Wuhan, China
Overview
Wuhan Renfukang Pharmaceutical Co., Ltd. was established in January 2016 with a registered capital of 150 million yuan. It is a subsidiary of the listed company Renfu Pharmaceutical Group (600079.SH) and a technology-based small and medium-sized enterprise. It is located in Wuhan East Lake New Technology Development Zone. The company is mainly engaged in drug production and research and development. It has four dosage form production lines: tablets, hard capsules, lyophilized powder injections and injections. In 2017, it obtained a drug production license and GMP approval for clinical drugs. In August 2019, it passed the FDA on-site audit and obtained FDA certification. As an open pharmaceutical preparation CMO/CDMO/mAh service platform, it focuses on the commissioned development and production of preparations (especially injection small batch clinical samples, orphan drugs, and precious concentrates), and provides integrated services at home and abroad from raw materials to formulations, clinical, BE, registration, and production.
Notes
Wuhan Humanwell Fukang Pharmaceutical Co., Ltd. is located at No. 666, Donghugaoxinqugaoxin Avenue Renfuyiyaodong, Wuhan, China.
Finished peptide dosage forms available.